Dovitinib in Neuroendocrine Tumors

Inclusion Criteria: * Patients with advanced, metastatic, recurrent or unresectable paraganglioma or pheochromocytoma. Pathology report or pathology slides (H\&E) confirming histological diagnosis must be available at the time of enrollment. * Must have measurable disease by RECIST v1.1. * ECOG performance status 0, 1, 2 * Age greater or equal to 18 years old * Adequate laboratory results; negative pregnancy test (females of childbearing potential) * Patients who give a written informed consent obtained according to institutional guidelines Exclusion Criteria: * Patients with known untreated brain metastases are excluded. Patients having a history of brain metastasis that have been previously irradiated or resected greater than 3 months prior to enrollment and are clinically and radiographically stable will be considered for enrollment. * Patients with another primary malignancy within 3 years prior to starting study drug, with the exception of adequately treated in-situ carcinoma of the uterine cervix, or skin cancer (such as basal cell carcinoma, squamous cell carcinoma, or non-melanomatous skin cancer) * Patients who have received the last administration of an anticancer therapy including chemotherapy, immunotherapy, hormonal therapy and monoclonal antibodies (but excluding nitrosurea, mitomycin-C, targeted therapy and radiation) less than or equal to 4 weeks prior to starting study drug, or who have not recovered from the side effects of such therapy * Patients who hav…